Source-grounded facts extracted from Synergy CHC Corp.'s SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
Synergy CHC Corp. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2), 5810(c)(3)(A)).
“May 15, 2026, Synergy CHC Corp. (the “Company”) received written notice (the “Notice”) from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that, based on the closing”
Synergy CHC Corp. reported the three months ended March 31, 2025 results: revenue $8.17 million, net income $0.88 million, EPS $0.10.
“$8.17 million. ● Gross margin of 72.3% vs. 75.4%. ● Income (loss) from operations of ($0.57) million”
Synergy CHC Corp. reported the three months ended March 31, 2026 results: revenue $5.49 million, net income ($2.57) million, EPS ($0.23).
“path, we expect 2026 to be a year of sustainable growth and value creation for our shareholders.” First Quarter 2026 Financial Summary vs. Same Year-Ago Period ● Revenue of $5.49 million vs. $8.17 million. ● Gross margin of 72.3% vs. 75.4%. ● Income (loss) from operations of ($0.57) million vs. $1.95 million. ● Net income (loss) of ($2.57) million vs.”
Synergy CHC Corp. entered into Purchase Agreement with Hudson Global Ventures, LLC valued at $36,000,000 (effective 2026-05-08).
“On May 8, 2026, Synergy CHC Corp. (the “Company”) entered into an equity purchase agreement (the “Purchase Agreement”) with Hudson Global Ventures, LLC (the “Investor”), pursuant to which the Company has the right, but not the obligation, to direct the Investor to purchase up to $36,000,000 of the Company’s common stock”
Synergy CHC Corp. issued 3,000,000 shares of warrant to Acme Credit Partners Fund I, LP for exercise price of $0.00001 per share.
“on March 24, 2026 the Company issued a common stock purchase warrant (the “Lender Warrant”) to Acme Credit Partners Fund I, LP (the “Holder”), a lender under the Credit Agreement. The Lender Warrant provides the Holder the right to purchase 3,000,000 shares of the Company’s common stock at an exercise price of $0.00001 per share.”
Synergy CHC Corp. amended Second Amendment with ACP Agency, LLC (effective 2026-03-24).
“On March 24, 2026, Synergy CHC Corp. (the “Company”) entered into a second amendment (the “Second Amendment”) to its term loan credit agreement”
Synergy CHC Corp.: Amendment to Articles of Incorporation to authorize issuance of up to 1,000,000 shares of Preferred Stock.
“At the Annual Meeting the Company’s stockholders approved an amendment (the “Certificate of Amendment”) to the Company’s Articles of Incorporation, as amended (the “Articles of Incorporation”), to authorize the issuance of up to 1,000,000 shares of preferred stock, par value $0.00001 per share (“Preferred Stock”).”
Synergy CHC Corp. incurred term loan of $15.0 million with ACP Agency, LLC at Term SOFR rate plus 8.50%.
“On May 30, 2025, Synergy CHC Corp. (the “Company”) entered into a term loan credit agreement (the “Credit Agreement”) with ACP Agency, LLC (“ACP”). The Credit Agreement consists of a $15.0 million term loan (the “Term Loan”), up to $2.5 million in a committed delayed draw facility (the “Delayed Draw Facility”), and up to $2.5 million in an uncommitted term loan incremental facility (the “Incremental Facility”)”
Jaime Fickett was appointed as Chief Financial Officer at Synergy CHC Corp..
“On March 27, 2025, the Board of Directors appointed Jaime Fickett, the Company’s current Interim Chief Financial Officer, to the position of Chief Financial Officer, effective immediately.”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.